FDA Advisory Committee Is Sign Of Grim Progress For Ferring’s Nocdurna
This article was originally published in The Pink Sheet Daily
Executive Summary
Ferring’s nocturia treatment seems headed for another rejection, but a chance to make its case at an advisory panel can be seen as a win for company’s 505(b)(2) desmopressin application.